Key clinical point: Live attenuated influenza vaccine does not increase the risk of lower respiratory events in children with asthma, compared with inactivated influenza vaccine.
Major finding: The adjusted ratio of rate ratios was 0.74 for events within 21 days of vaccination and 0.77 for events within 42 days of vaccination.
Study details: A retrospective cohort study of 4,771 children with asthma or recurrent wheezing who received influenza vaccine.
Disclosures: The research was funded by a grant from the National Institute of Allergy and Infectious Diseases. The authors had no relevant financial disclosures.
Nordin JD et al. Vaccine. 2019 Jun 10. doi: 10.1016/j.vaccine.2019.05.081.